Search

Displaying results 5631 - 5640 of 10000 in total
  1. Drug

    DA-697b

    go.drugbank.com/drugs/DB06001
    Experimental

    DA-967b is an investigational antiplatelet agent that inhibits collagen and ristocetin-mediated platelet activation.

  2. Drug

    FP-1096

    go.drugbank.com/drugs/DB05310
    Experimental

    FP1096 reduced the painful symptoms of endometriosis in trial subjects with very minimal side effect.

  3. Drug

    Ganstigmine

    go.drugbank.com/drugs/DB06525
    Experimental

    Ganstigmine is an orally active, geneserine derived, carbamate-based acetylcholinesterase inhibitor developed for the treatment of Alzheimer's disease.

  4. Drug

    Luliconazole

    go.drugbank.com/drugs/DB08933
    ApprovedInvestigational

    It was approved by the FDA (USA) in November 2013 and is marketed under the brand name Luzu. Luliconazole is also approved in Japan.

  5. Drug

    DCLL-9718S

    go.drugbank.com/drugs/DB17392
    Investigational

    DCLL9718S is under investigation in clinical trial NCT03298516 (A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine … DCLL9718S is an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1).

  6. Drug

    Aluminium monostearate

    go.drugbank.com/drugs/DB01375
    Experimental

    Also known as dihydroxyaluminium or dihydroxy(stearato)aluminium, it is used to form gels in the packaging of pharmaceuticals and in the preparation of colors for cosmetics. … While considered safe for use, extensive usage may result in aluminum accumulation.

  7. Drug

    KAI-1455

    go.drugbank.com/drugs/DB06064
    Experimental

    In preclinical studies, KAI-1455 showed a dramatic reduction in infarct size when delivered prior to the ischemic insult. … Several studies have demonstrated that epsilon PKC plays a key role in cytoprotection during periods of ischemia.

  8. Drug

    AK119

    go.drugbank.com/drugs/DB16423
    Investigational

    AK119 is a humanized anti-CD73 monoclonal antibody being investigated in the clinical trial NCT04516564 (A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects).[L28315]

  9. Drug

    Oxypurinol

    go.drugbank.com/drugs/DB05262
    Investigational

    Oxypurinol, an inhibitor of xanthine oxidase, is a metabolite of allopurinol.

  10. Drug

    Apadenoson

    go.drugbank.com/drugs/DB05009
    Investigational

    It is developed by Bristol-Myers Squibb and is in phase II of clinical trials. … Apadenoson is a selective A2a adenosine receptor agonist designed for use as a pharmacologic stress agent in cardiac perfusion imaging studies.